Steven Leonard Chapman Sells 3,076 Shares of Natera (NASDAQ:NTRA) Stock

Natera, Inc. (NASDAQ:NTRA) CEO Steven Leonard Chapman sold 3,076 shares of the firm’s stock in a transaction that occurred on Monday, August 3rd. The stock was sold at an average price of $266.39, for a total transaction of $819,415.64. Following the sale, the chief executive officer directly owned 99,897 shares of the company’s stock, valued at approximately $26,611,561.83. This trade represents a 2.99% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Steven Leonard Chapman also recently made the following trade(s):

• On Tuesday, July 28th, Steven Leonard Chapman sold 3,580 shares of Natera stock. The shares were sold at an average price of $254.07, for a total transaction of $909,570.60.
• On Monday, July 27th, Steven Leonard Chapman sold 2,190 shares of Natera stock. The shares were sold at an average price of $260.49, for a total transaction of $570,473.10.
• On Thursday, June 4th, Steven Leonard Chapman sold 41,124 shares of Natera stock. The stock was sold at an average price of $221.03, for a total transaction of $9,089,637.72.

Natera Trading Down 3.4%

NASDAQ:NTRA opened at $265.38 on Friday. Natera, Inc. has a 12 month low of $136.21 and a 12 month high of $288.04. The stock has a market capitalization of $38.01 billion, a price-to-earnings ratio of -162.81 and a beta of 1.51. The firm has a fifty day simple moving average of $252.06 and a two-hundred day simple moving average of $223.09.

Natera (NASDAQ:NTRA) last announced its quarterly earnings data on Thursday, August 6th. The medical research company reported ($0.47) earnings per share for the quarter, beating the consensus estimate of ($0.49) by $0.02. The firm had revenue of $752.75 million for the quarter, compared to analyst estimates of $661.24 million. Natera had a negative net margin of 9.05% and a negative return on equity of 14.74%. The business’s quarterly revenue was up 37.7% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.74) earnings per share. Equities analysts predict that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Natera

Several large investors have recently bought and sold shares of the stock. JPMorgan Chase & Co. boosted its holdings in Natera by 10.5% during the 4th quarter. JPMorgan Chase & Co. now owns 12,854,334 shares of the medical research company’s stock worth $2,944,800,000 after acquiring an additional 1,225,420 shares during the last quarter. Wellington Management Group LLP lifted its position in shares of Natera by 94.7% during the fourth quarter. Wellington Management Group LLP now owns 4,976,325 shares of the medical research company’s stock valued at $1,140,026,000 after purchasing an additional 2,420,263 shares in the last quarter. State Street Corp lifted its position in shares of Natera by 2.2% during the third quarter. State Street Corp now owns 3,389,599 shares of the medical research company’s stock valued at $545,624,000 after purchasing an additional 72,087 shares in the last quarter. Coatue Management LLC boosted its holdings in Natera by 1,446.1% during the fourth quarter. Coatue Management LLC now owns 2,633,334 shares of the medical research company’s stock worth $603,270,000 after purchasing an additional 2,463,008 shares during the last quarter. Finally, Geode Capital Management LLC boosted its holdings in Natera by 0.5% during the fourth quarter. Geode Capital Management LLC now owns 2,608,644 shares of the medical research company’s stock worth $596,078,000 after purchasing an additional 11,689 shares during the last quarter. 99.90% of the stock is currently owned by institutional investors.

Key Headlines Impacting Natera

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Natera reported second-quarter revenue of $752.8 million, up 37.7% year over year and well above analysts’ $661.2 million estimate. Its adjusted loss of $0.47 per share was also slightly better than the $0.49 consensus and improved from a $0.74 loss a year earlier. Gross margin increased to 64.5% from 63.4%. Natera Reports Second Quarter 2026 Financial Results
• Positive Sentiment: The company raised or reaffirmed full-year 2026 revenue guidance at approximately $2.9 billion, ahead of the roughly $2.8 billion analyst consensus. The outlook reinforces expectations for continued demand across Natera’s reproductive health, oncology, and transplant testing businesses.
• Positive Sentiment: Natera submitted its Signatera molecular residual disease test to Japan’s PMDA for approval as a companion diagnostic in muscle-invasive bladder cancer. Regulatory approval could expand Signatera’s international addressable market and create another source of oncology revenue. Natera Submits Signatera to Japan’s PMDA
• Neutral Sentiment: CEO Steven Leonard Chapman, CFO Michael Burkes Brophy, and other executives sold shares totaling about $2.0 million. The transactions were made under pre-arranged Rule 10b5-1 plans to cover tax withholding from vested equity awards, and the executives retained substantial holdings, limiting their value as a negative confidence signal.
• Negative Sentiment: Natera remains unprofitable, reporting a negative net margin and return on equity. Although the quarterly loss narrowed year over year, investors may be focused on the company’s path to sustained earnings, particularly after the stock’s sharp rise and proximity to its 52-week high.

Analysts Set New Price Targets

NTRA has been the subject of a number of research reports. Wolfe Research started coverage on Natera in a research note on Tuesday, June 2nd. They issued an “outperform” rating and a $260.00 price objective for the company. BTIG Research set a $275.00 target price on Natera and gave the stock a “buy” rating in a research report on Wednesday, June 24th. TD Cowen reissued a “buy” rating on shares of Natera in a research report on Wednesday, July 15th. Morgan Stanley boosted their price target on shares of Natera from $250.00 to $310.00 and gave the company an “overweight” rating in a research note on Thursday, July 9th. Finally, Zacks Research downgraded shares of Natera from a “hold” rating to a “strong sell” rating in a report on Tuesday, July 14th. Three investment analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating, three have issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $267.83.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.